We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

66 hedge funds and large institutions have $66.5M invested in Cartesian Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 19

0.75% less ownership

Funds ownership: 25.41% → 24.66% (-0.75%)

8% less funds holding

Funds holding: 72 → 66 (-6)

23% less capital invested

Capital invested by funds: $86.7M → $66.5M (-$20.2M)

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

Holders
66
Holders Change
-6
Holders Change %
-8.33%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
22
Reduced
19
Closed
14
Calls
$632K
Puts
–
Net Calls
+$632K
Net Calls Change
+$632K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$735K
2
Marshall Wace
Marshall Wace
United Kingdom
+$469K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$440K
4
GCP
GSA Capital Partners
United Kingdom
+$264K
5
Renaissance Technologies
Renaissance Technologies
New York
+$208K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$2.01M
2
MB
MPM BioImpact
Massachusetts
-$1.12M
3
Citadel Advisors
Citadel Advisors
Florida
-$281K
4
AA
ALPS Advisors
Colorado
-$256K
5
Goldman Sachs
Goldman Sachs
New York
-$208K
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
76
IFP Advisors
Florida
– -$13 -1 Closed
1 2 3
4

RNAC Hedge Fund Activity: Q2 2025 in Review

66 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2025, worth a combined $66.5M — down 23% from $86.7M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of RNAC and 8 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 22 added.

The largest buyer was 683 Capital Management, adding an estimated $735K. The largest seller was JP Morgan Chase, cutting an estimated $2.01M.

  • 66 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2025, down from 72 in Q1 2025.
  • Funds reported $66.5M of Cartesian Therapeutics stock for Q2 2025, down 23% quarter-over-quarter.
  • 8 funds opened new Cartesian Therapeutics positions in Q2 2025 and 14 closed out, a net change of -6 holders.
  • The largest Cartesian Therapeutics buyer in Q2 2025 was 683 Capital Management, an estimated $735K added.
  • The largest Cartesian Therapeutics seller in Q2 2025 was JP Morgan Chase, an estimated $2.01M sold.

Based on aggregated 13F filings for Q2 2025.